Key Takeaways:
Renal denervation (RDN) is a minimally invasive procedure that targets the nerves around the kidneys, which play a crucial role in regulating blood pressure. By disrupting these nerve signals, RDN helps lower blood pressure in patients with hypertension.
Clinical trials and recent data suggest that RDN can provide long-term blood pressure reduction, with effects lasting up to three years, offering an alternative to traditional medication-based treatments.
The market for RDN is growing rapidly, with a projected CAGR of 22% over the 2023-2028 forecast period, making it one of the fastest-growing segments in medtech.
Hypertension, also known as high blood pressure, affects roughly 1.3 billion adults across the globe. Despite the availability of medications, a significant portion of patients—approximately 10-12%, or 130-150 million people—find it hard to manage their blood pressure effectively, even when multiple medications are used.
This issue becomes even more pressing when considering patients who face challenges with medication adherence, often leading to the development of severe conditions like stroke.
RDN offers a promising solution to this persistent challenge. With renewed interest following two key regulatory approvals in late 2023, RDN is gaining momentum as a potential game-changer in hypertension treatment. Let’s explore how RDN works, its growing clinical support, and the opportunities it presents for both patients and the healthcare industry.
Renal denervation is a minimally invasive procedure designed to treat hypertension by targeting the renal nerves around the kidneys, which play a crucial role in regulating blood pressure. The procedure works by disrupting nerve activity that contributes to high blood pressure, leading to sustained reductions.
In November 2023, Medtronic and ReCor Medical received regulatory approval for their respective RDN solutions. Of the two, ReCor’s ultrasound-based Paradise System has shown particularly promising results in clinical trials, further advancing the field.
Recent trials have painted a positive picture for RDN. Medtronic’s Symplicity Spyral RDN system demonstrated significantly better results in reducing 24-hour ambulatory systolic blood pressure (ABPM) and office-based systolic blood pressure (OSBP) compared to placebo groups, with the effects remaining consistent over a two-year period.
The bottom line? Studies like SPYRAL and RADIANCE have shown that patients undergoing RDN experience meaningful drops in both office and 24-hour blood pressure measurements. What’s particularly exciting is that these results appear to persist for up to three years. While additional long-term data is needed, RDN represents a novel way to manage hypertension with fewer medications and less burden for patients.
The growth potential for renal denervation is significant. According to LSI’s Market Intelligence team, the market for RDN reached approximately $52.5 million at the end of 2024. Over the 2023-2028 forecast period, LSI projects the market will grow at a 22.0% CAGR, one of the highest growth rates among the more than 200 device markets covered by LSI’s Global Market Analysis and Projections.
However, there are challenges ahead. RDN currently lacks established reimbursement pathways in the United States, limiting its market expansion. This is a critical obstacle, as reimbursement policies directly impact the accessibility and affordability of medical treatments.
In medtech, CAGRs above 20% are rare, so this projected growth rate reflects the emerging nature of this market. If reimbursement issues are addressed within the forecast period, the market growth could exceed current expectations, making the potential for RDN even greater.
For the millions of people affected by hypertension, renal denervation offers a safe and effective alternative to traditional medication-based treatments. RDN could become an essential part of managing hypertension—particularly for patients who do not respond well to medications. We’re likely at the dawn of a new era in hypertension treatment, with RDN playing a key role in improving patient outcomes.
The future of renal denervation looks increasingly bright as it stands poised to become a mainstream treatment for hypertension. With the potential to offer lasting blood pressure reductions without the need for multiple medications, RDN could revolutionize the way we manage one of the most common chronic conditions worldwide.
As more clinical evidence becomes available and reimbursement pathways are established, the growth of RDN is expected to accelerate, making it a critical segment in the global medtech market. With its innovative approach to treating hypertension, RDN may become a key component in improving global cardiovascular health.
Gain access to the latest data and insights driving the medtech industry. Explore our Global Procedure Volumes Database to stay informed on key market trends and make data-driven decisions.
Looking for customized solutions? Reach out to our team of experts to discover how LSI’s Market Intelligence services can help you navigate industry changes and stay ahead of the competition.
Schedule an exploratory call
Request Info© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
